| Retinal Vein Occlusion
Byooviz vs Eylea HD
Side-by-side clinical, coverage, and cost comparison for retinal vein occlusion.Deep comparison between: Byooviz vs Eylea Hd with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEylea Hd has a higher rate of injection site reactions vs Byooviz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eylea Hd but not Byooviz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Byooviz
Eylea Hd
At A Glance
Intravitreal injection
Monthly
VEGF-A antagonist
Intravitreal injection
Every 8-16 weeks
VEGF-A/PlGF inhibitor
Indications
- Exudative age-related macular degeneration
- Retinal Vein Occlusion
- Myopic choroidal neovascularization
- Age related macular degeneration
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
- Retinal Vein Occlusion
Dosing
Exudative age-related macular degeneration 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days); may reduce to less frequent dosing after 3 initial monthly doses with regular assessment, or once every 3 months after 4 monthly doses.
Retinal Vein Occlusion 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days); patients should be treated monthly.
Myopic choroidal neovascularization 0.5 mg (0.05 mL) by intravitreal injection once monthly for up to 3 months; retreatment as needed.
Age related macular degeneration, Macular edema due to diabetes mellitus 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 doses, then once every 8 to 16 weeks (+/- 1 week); extended dosing once every 20 weeks (+/- 1 week) may be considered after 1 year of successful response.
Diabetic Retinopathy 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 doses, then once every 8 to 12 weeks (+/- 1 week).
Retinal Vein Occlusion 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 to 5 doses, then once every 8 weeks (+/- 1 week).
Contraindications
- Ocular or periocular infections
- Known hypersensitivity to ranibizumab products or any excipient in BYOOVIZ
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to aflibercept or any excipient in EYLEA HD
Adverse Reactions
Most common Conjunctival hemorrhage, eye pain, vitreous floaters, intraocular pressure increased, vitreous detachment, intraocular inflammation, cataract, nasopharyngitis, headache, bronchitis, arthralgia, upper respiratory tract infection
Serious Endophthalmitis, retinal detachments, thromboembolic events, serious intraocular inflammation
Postmarketing Tear of retinal pigment epithelium (neovascular AMD patients)
Most common (>=3%) Cataract, conjunctival hemorrhage, corneal epithelium defect, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, retinal hemorrhage, vision blurred, vitreous detachment, vitreous floaters
Serious Endophthalmitis, retinal detachments, retinal vasculitis with or without occlusion, increase in intraocular pressure, thromboembolic events
Postmarketing Retinal vasculitis, occlusive retinal vasculitis, scleritis
Pharmacology
VEGF-A antagonist; ranibizumab products bind to the receptor binding site of active forms of VEGF-A, preventing interaction with VEGFR1 and VEGFR2 on endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, inhibiting their binding and activation of VEGFR-1 and VEGFR-2, thereby suppressing neovascularization and vascular permeability in the eye.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Byooviz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
Eylea Hd
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Byooviz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Eylea Hd
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Byooviz
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Eylea Hd
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableByooviz Administration Copay Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ByoovizView full Byooviz profile
Eylea HdView full Eylea Hd profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.